These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Zheng C; Li L; Haak M; Brors B; Frank O; Giehl M; Fabarius A; Schatz M; Weisser A; Lorentz C; Gretz N; Hehlmann R; Hochhaus A; Seifarth W Leukemia; 2006 Jun; 20(6):1028-34. PubMed ID: 16617318 [TBL] [Abstract][Full Text] [Related]
4. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Zhao LJ; Wang YY; Li G; Ma LY; Xiong SM; Weng XQ; Zhang WN; Wu B; Chen Z; Chen SJ Blood; 2012 Mar; 119(12):2873-82. PubMed ID: 22318203 [TBL] [Abstract][Full Text] [Related]
5. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia. Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222 [TBL] [Abstract][Full Text] [Related]
6. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Adnan Awad S; Dufva O; Ianevski A; Ghimire B; Koski J; Maliniemi P; Thomson D; Schreiber A; Heckman CA; Koskenvesa P; Korhonen M; Porkka K; Branford S; Aittokallio T; Kankainen M; Mustjoki S Leukemia; 2021 Apr; 35(4):1087-1099. PubMed ID: 32782381 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations. Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566 [TBL] [Abstract][Full Text] [Related]
15. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia. Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030 [TBL] [Abstract][Full Text] [Related]
16. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia. Melo JV; Goldman JM Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550 [TBL] [Abstract][Full Text] [Related]
17. Differential display analysis of mRNAs in chronic myelogenous leukaemia. el-Awady MK; Abdalla NM; Salem AM; Samir S; Nour AM East Mediterr Health J; 2001; 7(4-5):707-15. PubMed ID: 15332769 [TBL] [Abstract][Full Text] [Related]
18. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis]. Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579 [TBL] [Abstract][Full Text] [Related]
19. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Grossmann V; Kohlmann A; Zenger M; Schindela S; Eder C; Weissmann S; Schnittger S; Kern W; Müller MC; Hochhaus A; Haferlach T; Haferlach C Leukemia; 2011 Mar; 25(3):557-60. PubMed ID: 21274004 [No Abstract] [Full Text] [Related]